The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...
A. deCamp, M. Juraska, Li Li et al.· Science Translational Medici...· 0 citations
The relationship between SARS-CoV-2-specific T cell responses and COVID-19 risk is incompletely understood, particularly after variant-adapted booster receipt. We assessed Spike-specific and Nucleocapsid-specific CD4+ and CD8+ T cell responses, measured by validated 27-color intracellular cytokine staining assay, as co...
Bo Zhang, You-Yi Fong, Chen-Chen Yu et al.· Nature Communications· 0 citations
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al.· Nature Communications· 1 citation
It is demonstrated that prophylactic VRC01 can select for viral escape after infection, underscoring the need for next-generation bnAbs with improved breadth and potency to enhance durability and efficacy of antibody-based HIV prevention.
Carolyn Williamson, Lyle Curry, N. Mkhize et al.· Nature Microbiology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.